Pulmonary Arterial Hypertension Global Market Report 2024

Pulmonary arterial hypertension refers to a condition characterized by elevated blood pressure in the arteries of the lungs, leading to damage to the right side of the heart and the lung arteries. This long-lasting and incurable condition results in the constriction and rigidity of the walls of the pulmonary arteries. Pulmonary arterial hypertension drugs are designed to address this condition by relaxing the muscles in the blood vessel walls, increasing blood flow through the lungs, or reversing the effects of substances in the blood vessel walls that cause them to narrow.

The main types of drug classes for pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. Endothelin receptor antagonists (ERAs) are a targeted medication used for treating pulmonary hypertension in patients. Targeted medications aim to reduce the progression of pulmonary hypertension and potentially reverse some of the damage to the heart and lungs. These drugs can be administered through oral, intravenous/subcutaneous, and inhalational modes, and they are distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $7.85 billion in 2023 to $8.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth observed in the historical period can be attributed to factors such as increased awareness and diagnosis of pulmonary arterial hypertension (PAH), a rise in healthcare expenditure, growth in the aging population, expansion of treatment options for pulmonary arterial hypertension, and an increase in research and development activities focused on pulmonary hypertension. These factors have collectively contributed to advancements in the understanding and management of pulmonary arterial hypertension, leading to improved diagnosis and treatment options.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $11.99 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to the adoption of novel therapies for pulmonary arterial hypertension, an increased focus on early detection and diagnosis, a growing pipeline of drugs and therapies for PAH, the integration of precision medicine in PAH treatment, and the expansion of healthcare infrastructure in emerging markets. Major trends expected in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, and an increased use of combination therapy. These trends reflect the ongoing efforts to enhance treatment options, early intervention, and overall patient care in the field of pulmonary arterial hypertension.

The growth of the pulmonary arterial hypertension market is being propelled by the increasing prevalence of pulmonary arterial hypertension (PAH) disease. The rise in PAH cases and the subsequent hospitalization of patients for treatment are expected to drive the demand for relevant drugs in the forecast period. According to the National Organization for Rare Disorders, Inc., a study suggests that new cases of PAH are estimated to occur in one to two individuals per million annually in the USA, equating to 500-1000 new cases each year, with similar incidence rates expected in Europe.

The pulmonary arterial hypertension market is anticipated to experience growth due to the increasing number of clinical trials for drug development. Clinical trials play a crucial role in assessing the safety, efficacy, and potential side effects of new drugs or treatments in humans. For pulmonary arterial hypertension drug development, these trials hold the promise of leading to the creation of more effective treatments, thereby improving the quality of life, enhancing safety and efficacy, providing early access, and identifying cost-effective treatments. Xtalks reported in May 2023 that there were 452,604 registered clinical studies on ClinicalTrials. gov, with 64,838 actively seeking participants - an increase of 365,000 registered trials in 2021. Hence, the surge in clinical trials for drug development is a key driver for the pulmonary arterial hypertension market.

Technological advancements stand out as significant trends gaining traction in the pulmonary arterial hypertension market. Companies in the pulmonary arterial hypertension drug sector are actively involved in developing new medicines to enhance and treat these diseases. For example, United Therapeutics Corporation, a US-based biotechnology company, launched Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease in April 2021. Tyvaso, an inhalation solution, aims to help patients improve exercise abilities, alleviate breathing difficulties, increase tolerance for exertion, and reduce mortality rates.

Major players in the pulmonary arterial hypertension market are strategically focusing on product approvals, such as Tyvaso, to drive revenues. Tyvaso (treprostinil) inhalation solution is prescribed to treat patients with interstitial lung disease (PH-ILD; WHO Group 3) and pulmonary hypertension, enhancing their activity capacity. In April 2021, United Therapeutics Corporation received FDA approval for Tyvaso, marking a significant advancement in treatment for individuals with PH-ILD.

In September 2021, Merck Group, a German-based multinational science and technology company specializing in healthcare and life sciences solutions, acquired Acceleron Pharma for $11 billion. This acquisition positions Merck at the forefront of rare disease-focused companies, providing ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication. Acceleron Pharma, a US-based company, is dedicated to researching, developing, and commercializing therapies for critical and uncommon conditions like pulmonary arterial hypertension.

Major companies operating in the in the pulmonary arterial hypertension market report are United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

North America was the largest region in the pulmonary arterial hypertension market in 2023. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.